 | |
| Clinical data | |
|---|---|
| Trade names | Detrol, Detrusitol, others |
| Other names | PNU-200583E |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a699026 |
| License data |
|
| Pregnancy category |
|
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | 77% |
| Protein binding | Approximately 96.3% |
| Elimination half-life | 1.9–3.7 hours |
| Identifiers | |
| |
| CAS Number |
|
| PubChem CID |
|
| IUPHAR/BPS | |
| DrugBank |
|
| ChemSpider |
|
| UNII |
|
| KEGG |
|
| ChEBI |
|
| ChEMBL |
|
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.232.068  |
| Chemical and physical data | |
| Formula | C22H31NO |
| Molar mass | 325.496 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
Tolterodine, sold under the brand name Detrol among others, is a medication used to treat frequent urination, urinary incontinence, or urinary urgency.[5] Effects are seen within an hour.[6] It is taken by mouth.[6][7]
Common side effects include headache, dry mouth, constipation, and dizziness.[6] Serious side effects may include angioedema, urinary retention, and QT prolongation.[6] Use in pregnancy and breastfeeding are of unclear safety.[5][8] It works by blocking muscarinic receptors in the bladder thus decreasing bladder contractions.[6]
Tolterodine was approved for medical use in 1998.[6] It is available as a generic medication.[5] In 2020, it was the 271st most commonly prescribed medication in the United States, with more than 1 million prescriptions.[9][10]
Detrusor overactivity (DO, contraction of the muscular bladder wall) is the most common form of urinary incontinence (UI) in older adults.[medical citation needed] It is characterized by uninhibited bladder contractions causing an uncontrollable urge to void.[medical citation needed] Urinary frequency, urge incontinence and nocturnal incontinence occur.[medical citation needed] Abnormal bladder contractions that coincide with the urge to void can be measured by urodynamic studies.[medical citation needed] Treatment is bladder retraining,[11][unreliable medical source?] pelvic floor therapy or with drugs that inhibit bladder contractions such as oxybutynin and tolterodine.[medical citation needed]
 |
This section does not cite any sources. Please help improve this sectionbyadding citations to reliable sources. Unsourced material may be challenged and removed. (May 2022) (Learn how and when to remove this message)
|
Known side effects:
The following reactions have been reported in people who have taken tolterodine since it has become available:
Tolterodine is not recommended for use in people with myasthenia gravis and angle closure glaucoma.
Tolterodine acts on M2 and M3[12] subtypes of muscarinic receptors whereas older antimuscarinic treatments for overactive bladder act more specifically on M3 receptors.[medical citation needed]
Tolterodine, although it acts on all types of receptors, has fewer side effects than oxybutynin (M3 and M1 selective, but more so in the parotid than in the bladder) as tolterodine targets the bladder more than other areas of the body.[medical citation needed]
It is marketed by Pfizer in Canada and the United States under the brand name Detrol. In Egypt it is also found under the trade names Tolterodine by Sabaa and Incont L.A. by Adwia.
In the US, Detrol is marketed by Viatris after Upjohn was spun off from Pfizer.[13][14][15]
|
Urologicals, including antispasmodics (G04B)
| |
|---|---|
| Acidifiers |
|
| Urinary antispasmodics (primarily antimuscarinics) |
|
| Other urologicals |
|
|
| |||||
|---|---|---|---|---|---|
| mAChRsTooltip Muscarinic acetylcholine receptors |
| ||||
| Precursors (and prodrugs) |
| ||||
| |||||
